 |
|
|
|
|
|
|
|
 |
Results for 'Pain Therapeutics' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Pain Therapeutics Inc -Therapeutic Competitors
|
February 2008 |
£175 |
99 % |
Pain Therapeutics
Drugs, Markets and Companies
|
September 2008 |
£1605 |
75 % |
Pain Therapeutics Inc -Financial Company Report
|
February 2008 |
£175 |
73 % |
Pain Therapeutics Inc -Detailed Product Pipeline
|
February 2008 |
£375 |
73 % |
Pain Therapeutics 2005
Market Dynamics and Outlook
|
May 2005 |
£990 |
50 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1515 |
45 % |
Premium Company Profile Pain Therapeutics
|
October 2007 |
£265 |
30.1 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1500 |
29.5 % |
Anesiva Inc
Premium Company Profile
|
April 2008 |
£265 |
26.5 % |
Chronotherapeutics
|
September 2003 |
£75 |
25.2 % |
Avigen Inc
Premium Company Profile
|
April 2008 |
£265 |
24 % |
TorreyPines Therapeutics Inc
Premium Company Profile
|
April 2008 |
£265 |
21 % |
Renovis
Premium Company Profile
|
December 2007 |
£265 |
21 % |
Premium Company Profile: Endo Pharmaceuticals
|
November 2007 |
£265 |
20.5 % |
Xenoport Inc
Premium Company Profile
|
December 2007 |
£265 |
20 % |
Purdue Pharma - SWOT Analysis
|
May 2007 |
£63 |
19.5 % |
Allergan: Pipeline , Products , Performance , Potential
|
February 2008 |
£595 |
19 % |
Labopharm Inc
Premium Company Profile
|
December 2007 |
£265 |
17.5 % |
Elan Corporation, plc - SWOT Analysis
|
June 2008 |
£63 |
17 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
16 % |
Pathology & Therapeutics for Pharmacists
3rd Edition
|
February 2008 |
£45 |
15.75 % |
5-HT7 antagonists
Novel molecules for the unmet migraine prophylaxis market
|
March 2003 |
£330 |
15.5 % |
Drug Delivery Companies Report, The
Autumn/Winter 2004
|
September 2004 |
£185 |
14.7 % |
Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain
|
January 2008 |
£1499 |
14 % |
Disease Management
|
January 2004 |
£29.95 |
13.65 % |
Innovations in CNS
Novel therapeutics and future R&D strategies
|
January 2007 |
£1495 |
12.5 % |
AstraZeneca
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
12.5 % |
Spectrum Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
12.5 % |
Watson Pharmaceuticals, Inc. - SWOT Analysis
|
September 2007 |
£125 |
12.5 % |
Companion Animal Behavioral Products
|
January 2007 |
£895 |
12.25 % |
Premium Company Profile Antares Pharma
|
November 2007 |
£265 |
12 % |
Merck & Co Pharmaceutical Company Intelligence Report
Pipeline Products Performance Potential
|
October 2007 |
£595 |
11.5 % |
Cannabinoids
A Potential Blockbuster
|
February 2005 |
£1499 |
11.2 % |
Medicinal Use of Cannabis and Cannabinoids
1st Edition
|
January 2004 |
£39.95 |
11.2 % |
Pfizer Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
11.2 % |
Injectable Drug Delivery: Market Impact and Industry Trends
|
October 2006 |
£870 |
10.5 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
10.15 % |
Valuing Pharmaceutical Innovation
Pricing and Reimbursement for Innovative Therapies
|
July 2008 |
£1995 |
9.8 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
9.8 % |
Nycomed
Pipeline Products Performance Potential
|
October 2007 |
£595 |
9.45 % |
Pfizer - Market Outlook for a Global Leader, 2008-2013
|
August 2008 |
£0 |
9.1 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
9.1 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1340 |
9.1 % |
Pipeline Insight: Neuropathic Pain
Emerging Drugs Fail To Capitalize In Lucrative Market
|
September 2007 |
£600 |
9.1 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£2410 |
8.4 % |
Drug Delivery Technology: Revolutionizing CNS Therapies
|
December 2007 |
£945 |
8.4 % |
Launching Combination Products
Brand Extension and Franchise Development Strategies
|
January 2008 |
£1995 |
8.05 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
8.05 % |
Diagnostics and Therapeutics for Genetic Diseases
|
April 2006 |
£2410 |
8.05 % |
Plant-Derived Drugs: Products, Technology, Applications
|
June 2006 |
£2410 |
7.7 % |
Dermatological and Cosmeceutical Development: Absorption Efficacy and Toxicity
|
August 2007 |
£130 |
7.7 % |
Stakeholder Opinions: Female Sexual Dysfunction
Results from Datamonitor's 2005 physician survey
|
June 2007 |
£2000 |
7.7 % |
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The
|
January 2007 |
£1115 |
7.35 % |
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
|
June 2008 |
£1995 |
7 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
7 % |
New Therapeutics and Diagnostics for Women’s Disorders
|
May 2005 |
£2255 |
7 % |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
7 % |
World Market for Sexual Disorders, 2005-2012, The
Traversing New Frontiers in Sexual Chemistry
|
January 2006 |
£1900 |
6.65 % |
Electrical and Magnetic Neurostimulation
Applications, Technologies, and Market Potential
|
September 2004 |
£1765 |
6.65 % |
Migraine
A market focus
|
August 2004 |
£885 |
6.3 % |
Pharmaceuticals in China
|
February 2006 |
£2385 |
5.95 % |
Scrip R&D Databook 2006
|
January 2006 |
£1295 |
5.95 % |
Pharmaceutical Regulatory Industry
|
January 2006 |
£2410 |
5.95 % |
The Pharmaceutical Market: Portugal
|
September 2007 |
£595 |
5.95 % |
Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets
Reshaping Tomorrow's Diabetes Market
|
October 2005 |
£990 |
5.6 % |
Radiation-based Therapy and Therapeutic Imaging
|
May 2005 |
£2255 |
5.6 % |
Pharma R&D Fact Book, The
2006
|
November 2007 |
£595 |
5.6 % |
Advanced Drug Delivery Systems: Probing the Route to Growth
New Developments, New Technologies, Companies and Trends
|
October 2001 |
£705 |
5.6 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
5.6 % |
Microelectronic Medical Implants
Products, Technologies & Opportunities
|
June 2001 |
£2410 |
5.6 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
5.6 % |
Cell Therapy Markets
|
July 2007 |
£1690 |
5.25 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£1605 |
5.25 % |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
5.25 % |
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
|
September 2004 |
£8000 |
5.25 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£1340 |
4.9 % |
U.S. Market for Gastrointestinal Pharmaceuticals
|
September 2005 |
£2255 |
4.55 % |
The OTC market in Poland
|
June 2006 |
£1050 |
4.55 % |
Virtual Reality Applications in Healthcare
U.S. Market
|
August 2007 |
£2015 |
4.55 % |
Pipeline Insight: Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
December 2006 |
£6000 |
4.55 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2140 |
4.55 % |
Patient Compliance in Psychiatry
From Patient Acquisition to Patient Retention
|
December 2004 |
£8000 |
4.2 % |
Stakeholder Insight: Prostate Cancer Treatment in the USA
|
September 2004 |
£8000 |
3.85 % |
Emerging Technologies in Spinal Motion Preservation
|
October 2006 |
£1295 |
3.85 % |
The Global Market for Advanced Wound Care Products 2007
|
March 2007 |
£695 |
3.85 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
3.85 % |
New Developments in Insulin Delivery Systems (2006)
|
June 2006 |
£495 |
3.85 % |
Medical Imaging: Reagents and Analysis Tools
|
December 2006 |
£2410 |
3.85 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2015 |
3.5 % |
Pipeline Insight: Endometriosis
Growing the Patient Population is Key to Unlocking the Market's Commercial Potential
|
July 2004 |
£6000 |
3.5 % |
Pipeline Insight: Anxiety Disorders
A decade of declining revenues
|
March 2006 |
£6495 |
3.5 % |
Billion Dollar Pharmaceuticals Club - Europe
Profiles of the Leading Europe Players
|
September 2000 |
£99 |
3.5 % |
Pediatric Drugs: the Worldwide Market
3rd Edition
|
December 2007 |
£2015 |
3.15 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
3.15 % |
Medtronic Medical Device Company Intelligence Report
|
September 2006 |
£395 |
2.45 % |
World Gastrointestinal Disorders Market 2006-2011; The
|
January 2006 |
£1799 |
2.45 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
2.45 % |
Generic League
Market Analysis and Forecasts, 2007-2012, 2017 & 2022
|
February 2008 |
£1999 |
2.1 % |
Cell Therapy
Technologies, Markets and Companies
|
September 2008 |
£2410 |
2.1 % |
Gastrointestinal Disorders Market Intelligence to 2012
|
May 2007 |
£1499 |
2.1 % |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
1.75 % |
Launch Strategies - Analyzing Market Trends and Regulatory Impacts
|
August 2007 |
£8010 |
1.4 % |
|
|
|
|
